Patient characteristics.

<p>Patient characteristics were comparable in patients with low (CFI<0.39) and high (CFI>0.39) collateral capacity, with the exception of a greater incidence of hypercholesterolemia in the high collateral capacity group. ACE, Angiotensin converting enzyme; ARBs, angiotensin receptor blockers; BMI, body mass index; CAD, coronary artery disease; CFI, collateral flow index; LAD, left anterior descending; RCA, right coronary artery; RCX, right circumflex.</p><p>Patient characteristics.</p

Receiver operating characteristic curves.

<p>Properties of receiver operator characteristic curves shows that miR126 levels can significantly discriminate between patients with low CFI (<0.39) versus high CFI (>0.39), with a p-value <0.01. In addition, in a multivariate logistic regression model with age and gender, each of the select miRNAs show significant predictive power to discriminate between patients with high or low collateral capacity.</p><p>*Multivariate logistic regression model. AUC, area under curve; CI, confidence interval; CFI: collateral flow index; LR, likelihood ratio; miRNA, microRNA; N/A, not applicable.</p><p>Receiver operating characteristic curves.</p

Diagnostic potential of miRNAs.

<p>Receiver operator characteristic curve analysis of individual miRNAs (A: miR423-5p; B: miR30d; C: miR10b; D: miR126) and multivariate logistic regression models of individual microRNAs together with age and gender (E: miR423-5p; F: miR30d; G: miR10b; H: miR126) to discriminate between high or low collateral capacity patients. Red line depicts sensitivity (%) as a function of 1- specificity (%). The black line depicts the identity line. The greater the area between the ROC curve (red) and identity line (black), the more accurate the test and the larger the discriminatory power of the test. Multivariate logistic regression models with age and gender increase the area under the curve (AUC) of each miRNA, and thus improve their power to discriminate between patients with either high or low collateral capacity.</p

Frequency distribution of collateral flow index (CFI) in patient group (n = 41).

<p>Patients were dichotomized into two groups, low (CFI <0.39) and high (CFI>0.39) collateral capacity</p

Novel molecular imaging ligands targeting matrix metalloproteinases 2 and 9 for imaging of unstable atherosclerotic plaques - Fig 3

<p><b>Synthesis of 10 a-d.</b> (i): HN(CH₂COOH, THF/H₂O, rt, o/n, yield 3–35%; (ii): HN(CH₂CO₂<i>t</i>bu)₂, TEA, DCM, rt, o/n, 78–99%; (iii): HCOOH, rt, o/n, yield 75–94%; (iv): ECF, NMM, THF, NH₂OH x HCl, MeOH, 0°C, 2 h, yield 52–91%.</p

Expression of microRNAs in healthy individuals and CTO patients.

<p>Values are based on qPCR measurements. Data are presented as mean ± SD. CTO: chronic total occlusion.</p

Synthesis of hydroxamate target compound 4a-e from 1a-e.

<p>(i): HN(CH₂CO₂<i>t</i>bu)₂,TEA, DCM, rt, o/n, yield 39–75%; (ii): HCOOH, rt, o/n, yield 30–93%; (iii): ECF, NMM, THF, NH₂OH x HCl, MeOH, 0°C, 2 h, yield 63–97%.</p

Radiosynthesis of [¹²³I]10c from 10d by nucleophilic radioiodination.

<p>(i): Na[¹²³I]I, ethanol, citric acid, 2,5 dihydroxybenzoic acid, CuSO₄, SnSO_4, 130°C, 40 min, yield 51%.</p

MMP inhibitory potencies of compounds 4a-e and 10a-d.

<p>IC₅₀: half maximal inhibitory concentration. Values expressed in nM are presented as mean ± SD of three independent experiments in duplicate. Selectivity was calculated as the ratio of IC₅₀ values; MMP1 IC₅₀ for each respective compound was divided by the respective MMP2 or MMP9 IC₅₀. The higher the selectivity value, the greater the selectivity towards either MMP2 or MMP9 relative to MMP1 for each respective compound.</p

List of halogenated forms of two sulfonamide hydroxamate based compounds examined.

<p>List of halogenated forms of two sulfonamide hydroxamate based compounds examined.</p